CYTK
Price
$32.30
Change
+$0.22 (+0.69%)
Updated
Jun 6 closing price
Capitalization
3.86B
54 days until earnings call
INNMF
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Jun 6 closing price
Capitalization
16.62M
Interact to see
Advertisement

CYTK vs INNMF

Header iconCYTK vs INNMF Comparison
Open Charts CYTK vs INNMFBanner chart's image
Cytokinetics
Price$32.30
Change+$0.22 (+0.69%)
Volume$768.26K
Capitalization3.86B
Amplia Therapeutics
Price$0.04
Change-$0.00 (-0.00%)
Volume$550
Capitalization16.62M
CYTK vs INNMF Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. INNMF commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and INNMF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (CYTK: $32.30 vs. INNMF: $0.04)
Brand notoriety: CYTK and INNMF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 35% vs. INNMF: 1%
Market capitalization -- CYTK: $3.86B vs. INNMF: $16.62M
CYTK [@Biotechnology] is valued at $3.86B. INNMF’s [@Biotechnology] market capitalization is $16.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileINNMF’s FA Score has 1 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • INNMF’s FA Score: 1 green, 4 red.
According to our system of comparison, INNMF is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish.

  • CYTK’s TA Score: 5 bullish, 3 bearish.

Price Growth

CYTK (@Biotechnology) experienced а +4.13% price change this week, while INNMF (@Biotechnology) price change was -6.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($3.86B) has a higher market cap than INNMF($16.6M). INNMF YTD gains are higher at: -15.254 vs. CYTK (-31.335). INNMF has higher annual earnings (EBITDA): -6.01M vs. CYTK (-513.62M).
CYTKINNMFCYTK / INNMF
Capitalization3.86B16.6M23,241%
EBITDA-513.62M-6.01M8,539%
Gain YTD-31.335-15.254205%
P/E RatioN/AN/A-
Revenue19.2MN/A-
Total Cash938MN/A-
Total Debt791MN/A-
FUNDAMENTALS RATINGS
CYTK vs INNMF: Fundamental Ratings
CYTK
INNMF
OUTLOOK RATING
1..100
444
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
8860
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INNMF's Valuation (18) in the null industry is significantly better than the same rating for CYTK (100) in the Biotechnology industry. This means that INNMF’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (84) in the Biotechnology industry is in the same range as INNMF (100) in the null industry. This means that CYTK’s stock grew similarly to INNMF’s over the last 12 months.

INNMF's SMR Rating (94) in the null industry is in the same range as CYTK (99) in the Biotechnology industry. This means that INNMF’s stock grew similarly to CYTK’s over the last 12 months.

INNMF's Price Growth Rating (60) in the null industry is in the same range as CYTK (88) in the Biotechnology industry. This means that INNMF’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for INNMF (100) in the null industry. This means that CYTK’s stock grew significantly faster than INNMF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTK
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
71%
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GABGX116.74N/A
N/A
Gabelli Growth AAA
FSATX16.01N/A
N/A
Fidelity Advisor Asset Manager 60% M
MSVYX17.45N/A
N/A
MassMutual Small Cap Opps Svc
VVPSX11.79N/A
N/A
Vulcan Value Partners Small Cap
VFFSX291.21N/A
N/A
Vanguard 500 Index Institutional Select

INNMF and

Correlation & Price change

A.I.dvisor tells us that INNMF and BIVI have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INNMF and BIVI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INNMF
1D Price
Change %
INNMF100%
-10.49%
BIVI - INNMF
26%
Poorly correlated
-0.92%
HOFBF - INNMF
23%
Poorly correlated
N/A
CYTK - INNMF
23%
Poorly correlated
+0.69%
PHRRF - INNMF
20%
Poorly correlated
+3.27%
IVEVF - INNMF
15%
Poorly correlated
N/A
More